This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex Syringe

This study has been completed.
Information provided by:
Biogen Identifier:
First received: June 5, 2009
Last updated: NA
Last verified: June 2009
History: No changes posted
Determine patient satisfaction with the single-use autoinjector for the delivery of pre-filled Avonex syringe.

Condition Intervention Phase
Multiple Sclerosis Drug: Interferon beta-1a Device: Single-use autoinjector Phase 3

Study Type: Interventional
Study Design: Intervention Model: Crossover Assignment
Masking: Open Label
Official Title: An Open-Label, Multicenter Study to Determine Subject Satisfaction in Using the Single-Use Autoinjector With a Pre-Filled Liquid AVONEX® Syringe in Multiple Sclerosis Subjects

Resource links provided by NLM:

Further study details as provided by Biogen:

Primary Outcome Measures:
  • The primary objective of the study is to determine patient satisfaction with the single-use autoinjector for the delivery of pre-filled AVONEX® syringe [ Time Frame: The study duration is 8 Weeks ]

Enrollment: 74
Study Start Date: August 2005
Study Completion Date: April 2006
Primary Completion Date: April 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1st Injection
Manual injection with pre-filled syringe.
Drug: Interferon beta-1a
30mcg, IM once-a-week
Other Name: Avonex
Experimental: Single-use autoinjector
Single-use autoinjector with Avonex pre-filled syringe
Device: Single-use autoinjector
Single-use autoinjector with Avonex 30mcg pre-filled syringe


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must be using liquid AVONEX® to treat MS. In addition, the subject must be on liquid AVONEX® for 12 weeks prior to the Screening Visit.
  • Must have a BMI of 19 to 28 kg/m², inclusive, and a minimum body weight of 50 kg at Screening.
  • Must be able to physically demonstrate use of the device and be able to self-administer all injections.
  • Must be English speaking.
  • Must be able to understand and comply with the protocol.

Exclusion Criteria:

  • Abnormal screening or screening blood tests determined to be clinically significant by the investigator for: white blood count (WBC) or differential, platelet count, hemoglobin, serum creatinine, bilirubin, alanine transaminase (ALT) aspartate transaminase (AST), prothrombin time (PT).
  • Known sensitivity to dry natural rubber.
  • Treatment with other agents to treat MS symptoms or underlying disease as specified in the protocol.
  • History of severe allergic or anaphylactic reactions.
  • History of intolerance to acetaminophen (paracetamol), ibuprofen, naproxen, and aspirin that would preclude the use of at least one of these during the study.
  • Serious local infection

Other inclusion and exclusion criteria apply as per Biogen Idec Protocol

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00915577

Sponsors and Collaborators
Study Director: Biogen-Idec Investigator Biogen
  More Information

Responsible Party: Biogen Idec MD, Biogen Idec Identifier: NCT00915577     History of Changes
Other Study ID Numbers: C-872
Study First Received: June 5, 2009
Last Updated: June 5, 2009

Keywords provided by Biogen:
Multiple Sclerosis
interferon beta-1a
liquid Avonex

Additional relevant MeSH terms:
Multiple Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Interferon beta-1a
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Immunologic Factors
Physiological Effects of Drugs
Adjuvants, Immunologic processed this record on July 24, 2017